ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Alleviates the Defective Epididymis and Sperm Function in Lipopolysaccharide (LPS) Induced Acute Mouse Epididymitis.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
This study investigated the protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against lipopolysaccharide (LPS)-induced acute epididymitis in mice, with a particular emphasis on its antioxidant and anti-inflammatory mechanisms within the epididymal microenvironment responsible for sperm maturation. Acute epididymitis was triggered by injecting LPS intraperitoneally, with concurrent PACAP administration. Epididymal tissues were collected for histological, immunofluorescence, RT-PCR, and in vitro fertilization analyses. The results demonstrated that PACAP markedly decreased the expression of Il-6 mRNA (2.87 fold decrease, p < 0.05) and Tnf-α mRNA (2.45 fold decrease, p < 0.05) in the cauda epididymis following LPS adminstration for 6 h, alleviated histopathological changes, and improved sperm motility (from 37.8 ± 4.1% in LPS group to 52.7 ± 3.3% in LPS + PACAP group, p < 0.05) and morphology (abnormal sperm rate decreased from 45.7% ± 5.6-22.1% ± 3.8%, p < 0.05). PACAP also preserved the expression of epididymal function-associated proteins (AQP1 and KRT5), suppressed inflammatory gene expression, and enhanced antioxidant gene expression in the cauda epididymidis tissues during acute epididymitis. In vitro fertilization experiments revealed that PACAP significantly restored sperm fertilizing capacity, as evidenced by an increase in sperm-oocyte binding (from 8.7 ± 1.5 to 15.6 ± 2.7, p < 0.05), and improved embryonic development rates compromised by LPS (the two-cell embryo rate increased from 35.7% ± 4.8-62.3% ± 5.1%, p < 0.05). These results demonstrated that PACAP exerted a protective effect by suppressing inflammation and oxidative stress in acute epididymitis, thereby preserving epididymal function and sperm quality. PACAP may represent a potential therapeutic agent for epididymitis and related fertility issues.
Indexed as
Identifiers
40640589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.